Which has preferable earnings and valuation, TARA or PMVP?

Protara Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is TARA or PMVP more profitable?

Protara Therapeutics' return on equity of -38.70% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% PMV Pharmaceuticals N/A -68.98% -62.70%

Do analysts rate NLTX or PMVP?

PMV Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 371.70%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings & valuation, NLTX or PMVP?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is NLTX or PMVP more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% PMV Pharmaceuticals N/A -68.98% -62.70%

Is QTTB or PMVP more profitable?

Q32 Bio's return on equity of 149.23% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 149.23% 34.50% PMV Pharmaceuticals N/A -68.98% -62.70%

PMV Pharmaceuticals (PMVP) Competitors

$1.06 +0.01 (+0.95%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 +0.00 (+0.47%)

As of 04:26 PM Eastern

Compare

PMVP vs. TARA, NLTX, ACIU, CHRS, and QTTB

Should you buy PMV Pharmaceuticals stock or one of its competitors? MarketBeat compares PMV Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PMV Pharmaceuticals include Protara Therapeutics (TARA), Neoleukin Therapeutics (NLTX), AC Immune (ACIU), Coherus Oncology (CHRS), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry.

How does PMV Pharmaceuticals compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Protara Therapeutics' return on equity of -38.70% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Protara Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Protara Therapeutics presently has a consensus target price of $26.25, indicating a potential upside of 594.44%. PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 371.70%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Protara Therapeutics is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Protara Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

In the previous week, Protara Therapeutics had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 2 mentions for Protara Therapeutics and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.66 beat Protara Therapeutics' score of 0.44 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Protara Therapeutics	Neutral
PMV Pharmaceuticals	Positive

38.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 7.6% of Protara Therapeutics shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Protara Therapeutics beats PMV Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

In the previous week, PMV Pharmaceuticals had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for PMV Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. PMV Pharmaceuticals' average media sentiment score of 0.66 beat Neoleukin Therapeutics' score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
PMV Pharmaceuticals	Positive

Neoleukin Therapeutics' return on equity of -37.22% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

PMV Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 371.70%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Summary

PMV Pharmaceuticals beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to AC Immune?

AC Immune (NASDAQ:ACIU) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

AC Immune presently has a consensus target price of $7.50, indicating a potential upside of 253.77%. PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 371.70%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

AC Immune has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, AC Immune and AC Immune both had 1 articles in the media. AC Immune's average media sentiment score of 1.45 beat PMV Pharmaceuticals' score of 0.66 indicating that AC Immune is being referred to more favorably in the media.

Company	Overall Sentiment
AC Immune	Positive
PMV Pharmaceuticals	Positive

PMV Pharmaceuticals has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. PMV Pharmaceuticals' return on equity of -68.98% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-1,788.02%	-125.26%	-40.85%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

PMV Pharmaceuticals has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	50.06	-$85.03M	-$0.82	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Summary

PMV Pharmaceuticals beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Coherus Oncology has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market.

Coherus Oncology currently has a consensus target price of $8.67, indicating a potential upside of 537.25%. PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 371.70%. Given Coherus Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Coherus Oncology is more favorable than PMV Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Coherus Oncology and Coherus Oncology both had 1 articles in the media. Coherus Oncology's average media sentiment score of 1.89 beat PMV Pharmaceuticals' score of 0.66 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Coherus Oncology	Very Positive
PMV Pharmaceuticals	Positive

Coherus Oncology has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	4.97	$168.02M	$1.67	0.81
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to PMV Pharmaceuticals' net margin of 0.00%. PMV Pharmaceuticals' return on equity of -68.98% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Summary

Coherus Oncology beats PMV Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Q32 Bio and Q32 Bio both had 1 articles in the media. Q32 Bio's average media sentiment score of 0.94 beat PMV Pharmaceuticals' score of 0.66 indicating that Q32 Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Q32 Bio	Positive
PMV Pharmaceuticals	Positive

Q32 Bio has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 40.0% of Q32 Bio shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Q32 Bio has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.06	$29.82M	$2.66	4.84
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Q32 Bio's return on equity of 149.23% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	149.23%	34.50%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Q32 Bio currently has a consensus price target of $13.50, suggesting a potential upside of 4.90%. PMV Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 371.70%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe PMV Pharmaceuticals is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Q32 Bio beats PMV Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get PMV Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMVP vs. The Competition

Export

Metric	PMV Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.53M	$2.94B	$6.41B	$11.71B
Dividend Yield	N/A	1.71%	2.67%	5.55%
P/E Ratio	-0.71	17.80	24.46	23.62
Price / Sales	N/A	289.23	500.50	105.26
Price / Cash	N/A	55.74	42.36	56.09
Price / Book	0.54	3.88	10.43	6.70
Net Income	-$77.74M	$75.85M	$3.56B	$337.26M
7 Day Performance	-8.62%	-1.87%	-1.39%	-1.41%
1 Month Performance	-24.82%	-6.20%	0.86%	1.15%
1 Year Performance	-10.92%	12.60%	19.42%	22.61%

PMV Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMVP PMV Pharmaceuticals	2.6752 of 5 stars	$1.06 +1.0%	$5.00 +371.7%	-0.9%	$56.53M	N/A	N/A	50	News Coverage Analyst Upgrade
TARA Protara Therapeutics	2.9168 of 5 stars	$4.41 +4.5%	$26.25 +495.2%	+21.4%	$247.84M	N/A	N/A	30	Short Interest Increase
NLTX Neoleukin Therapeutics	N/A	$26.22 +0.3%	N/A	+31.0%	$246.42M	N/A	N/A	90
ACIU AC Immune	2.918 of 5 stars	$2.40 +0.4%	$7.50 +212.5%	+7.6%	$244.25M	$4.31M	N/A	140	Positive News
CHRS Coherus Oncology	3.663 of 5 stars	$1.58 +7.1%	$8.67 +450.3%	+66.2%	$242.94M	$42.17M	0.94	330	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMVP) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. TARA, NLTX, ACIU, CHRS, and QTTB

How does PMV Pharmaceuticals compare to Protara Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Neoleukin Therapeutics?

Summary

How does PMV Pharmaceuticals compare to AC Immune?

Summary

How does PMV Pharmaceuticals compare to Coherus Oncology?

Summary

How does PMV Pharmaceuticals compare to Q32 Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. TARA, NLTX, ACIU, CHRS, and QTTB

How does PMV Pharmaceuticals compare to Protara Therapeutics?

Is TARA or PMVP more profitable?

Which has more risk and volatility, TARA or PMVP?

Do analysts recommend TARA or PMVP?

Which has preferable earnings and valuation, TARA or PMVP?

Does the media favor TARA or PMVP?

Do institutionals & insiders believe in TARA or PMVP?

Summary

How does PMV Pharmaceuticals compare to Neoleukin Therapeutics?

Does the media refer more to NLTX or PMVP?

Is NLTX or PMVP more profitable?

Do analysts rate NLTX or PMVP?

Do institutionals and insiders have more ownership in NLTX or PMVP?

Which has better earnings & valuation, NLTX or PMVP?

Which has more risk and volatility, NLTX or PMVP?

Summary

How does PMV Pharmaceuticals compare to AC Immune?

Do analysts rate ACIU or PMVP?

Which has more volatility & risk, ACIU or PMVP?

Do insiders & institutionals have more ownership in ACIU or PMVP?

Does the media favor ACIU or PMVP?

Is ACIU or PMVP more profitable?

Which has higher earnings and valuation, ACIU or PMVP?

Summary

How does PMV Pharmaceuticals compare to Coherus Oncology?

Which has more risk & volatility, CHRS or PMVP?

Do analysts prefer CHRS or PMVP?

Does the media refer more to CHRS or PMVP?

Which has stronger earnings & valuation, CHRS or PMVP?

Do insiders and institutionals believe in CHRS or PMVP?

Is CHRS or PMVP more profitable?

Summary

How does PMV Pharmaceuticals compare to Q32 Bio?

Does the media refer more to QTTB or PMVP?

Which has more volatility & risk, QTTB or PMVP?

Do institutionals and insiders have more ownership in QTTB or PMVP?

Which has better valuation & earnings, QTTB or PMVP?

Is QTTB or PMVP more profitable?

Do analysts recommend QTTB or PMVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools